WHAT IS EHEP (SOFOSBUVIR)?
EHEP is Sofosbuvir which is a drug used as part of antiviral therapy against chronic hepatitis C virus, EHEP (Sofosbuvir) is an HCV polymerase inhibitor. These drugs prevent the polymerase enzyme from working. This makes it harder for the virus to multiply. EHEP (Sofosbuvir) is the first drug that inhibits HCV polymerase. It is the fourth drug that directly interferes with the virus. Earlier drugs used to treat HCV were general immune boosters,interferon and ribavirin (IFN and RBV), EHEP (Sofosbuvir) must be used in combination with other HCV medications. The combination of medications depends on the strain or Genotype of HCV. EHEP (Sofosbuvir) should not be used by itself.
WHO SHOULD TAKE IT?
EHEP (Sofosbuvir) is approved in india in 2015 march, Where as EHEP (Sofosbuvir) was approved in 2013 as a direct antiviral drug for people infected with any HCV genotype, with HCV/HIV co-infection or people with liver cancer who are awaiting a transplant. EHEP (Sofosbuvir) has not been studied in people under the age of 18.
EHEP (Sofosbuvir) is taken by mouth as one 400 milligram (mg) tablet once day, with or without food.
1/a, Empress Business Bay, Near Uti Mutual Fund, Road No 11, Midc-Andheri East, Mumbai, Maharashtra, 400093, India